Erleada patent expiry?

Erleada (enzalutamide) – Patent Landscape & Expiry Dates

How the dates are calculated

• Standard U.S. patents: 20 years from the filing date (not the issue date).
• Orphan‑drug and first‑to‑file extensions (up to 5 years) can be added if the drug received orphan‑drug status, but these were not applied to the core enzalutamide patents.
• Patent term adjustments (e.g., for regulatory review delays) can add a few months, but the above dates are the most commonly cited expiries.

Practical implications

1. First patent (US 7,292,816) – core molecule

   • The earliest generic‑entry‑eligible date in the U.S. is late 2026/early 2027.
   • Even if a generic company could manufacture enzalutamide, it would still be barred from selling it under the name “Erleada” until this patent expires.

2. Secondary patents (US 8,212,380, US 9,111,912, WO 2011/007…)

   • These cover formulations, crystal forms, and specific therapeutic claims.
   • They extend the “generic‑safe‑to‑market” window to 2030–2035 in many jurisdictions.

3. International coverage

   • European patents covering the same chemistry expire around 2030.
   • In Japan and other markets, the expiration dates align closely with the U.S. core patent.

Current status

• No approved generic of erleada is available in the U.S. or EU as of 2026.
• Generic manufacturers are actively preparing for the 2026–2027 window but must also consider the secondary patents that may delay commercialization until 2030–2035.
• The FDA’s “patent term extension” program (if applicable) has not yet been granted for enzalutamide’s core patents.

Bottom line

• U.S. core‑molecule patent expires 2026‑27.
• Additional formulation/therapeutic patents keep the generic launch window until 2030‑35 in most markets.

So, while the primary patent for the enzalutamide chemical ends in 2026‑27, the practical ability for a generic competitor to enter the market is likely post‑2030 due to the suite of companion patents.